Skip to main content
Premium Trial:

Request an Annual Quote

NuGen Technologies Gets Phase I SBIR Grant for RNA Amplification Tech

NEW YORK, Oct. 7 (GenomeWeb News) - NuGen Technologies of San Carlos, Calif., said today that it has received a Phase I grant from the NIH to develop its nucleic acid amplification and detection technologies.

 

The company markets an Ovation RNA amplification system for gene expression, using its singler primer isothermal amplification (SPIA) technology, "a novel means of isothermal linear gene amplification," according to the grant abstract. This technology is incorporated into the company's Ribo-Spia method for isothermal linear RNA amplification, for which it has filed a patent application.

 

These technologies are designed to be sensitive enough to amplify up samples for small numbers of cells or single cells from tissue biopsies, laser capture microdissection, and other methods of tissue procurement. The company said it plans to use the grant to validate its technologies for this small-sample amplification.

The company did not disclose the amount of the grant, but typical SBIR Phase 1 grants are in the realm of $100,000.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.